Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD

• Visucomplex Plus (Dietary supplement): capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.

Primary outcomes

• Improvement of QoL in patients affected by AMD (dry or wet) measured through a questionnaire self-administered by the patient partially derived from the VFQ-25, aiming to define a new assessment instrument coupled with the routinely clinical follow up. [measured at baseline and after 4-8 and 12 months of treatment.]: QoL measured through a new questionnaire self-administered

Secondary outcomes

• Comparison of improvement scoring of QoL between VFQ-25 and a newly conceived questionnaire [measured at baseline and after 4-8 and 12 months of treatment.]: Comparison of improvement scoring of Quality of Life between the two questionnaires (VFQ-25 and a newly conceived one) at baseline and after 4-8 and 12 months of treatment. VFQ-25 is a valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ).
• Visual acuity [measured at baseline and after 4-8 and 12 months of treatment.]: Evaluation of disease progression through Visual acuity.
• OCT [measured at baseline and at the end of the observation period (12 months).]: Evaluation of disease progression through Optical Coherence Tomography (OCT).
• Questionnaire completion compliance [measured at the end of the observation period (12 months).]: Evaluation of improvement of completion compliance of the new questionnaire versus standard of care one (VFQ-25). VFQ-25 is a valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ).
• Likert scales (5 points) [measured at baseline and after 4-8 and 12 months of treatment.]: Evaluation of Patient's treatment judgement and improvement of condition (Likert Scales). A Likert scale is a rating scale where patients have to indicate their treatment judgement and improvement of condition crossing a score from 1 to 5.
• subject and investigator satisfaction: questionnaire [measured at baseline and after 4-8 and 12 months of treatment.]: Evaluation of subject and investigator satisfaction of the new questionnaire. Subject and investigator satisfaction is to be indicated on a scale crossing a score from 1 to 5.

Sex: All

Inclusion Criteria:

* Patient Informed consent form (ICF) signed
* Adult male and female irrespective of their age at the time of the signature of ICF
* Patients affected by dry or wet AMD irrespective of the disease severity and including newly diagnosed patients
* Patients with no treatment for AMD or under treatment with stable doses of anti-VEGF
* Willing to follow all study procedures, including attending all site visits, tests and examinations.

Exclusion Criteria:

* Previously diagnosed optic neuropathies
* Decompensated diabetes or hypertension
* Retinal pathologies including hereditary forms
* Neurological, Neurodegenerative or Cerebrovascular conditions
* Patients with a significantly progressive opacity of lens in the previous 3 months prior to enrolment
* Surgical intervention for cataract in the previous 3 months prior to enrolment
* Previously diagnosed eye inflammatory conditions (uveitis) in the previous 3 months
* Refractive defects beyond the 5 spherical diopters, both positive and negative and over 3 cylindrical
* Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular or hematological disease,
* Known drug and/or alcohol abuse
* Mental incapacity that precludes adequate understanding or cooperation
* Participation in another clinical study.